I Review Medical Equipment Quality for a Living. The Cheapest Price Is Usually the Most Expensive.

If you're still choosing medical equipment by the list price, you're not making a purchasing decision. You're guessing.

I say that from the boring side of medical technology. I'm a quality and brand compliance manager at a medical device company. Before anything reaches a customer, someone has to check the IFU, the label, the sterilization claims, the reprocessing instructions, and the complaint history. I do that work. I also sit through procurement evaluations from time to time, because every quality issue eventually becomes a purchasing question. In 2024 I rejected roughly 14% of first-draft clinical claims I reviewed because they didn't match the technical file. So when I tell you the cheapest price is usually the most expensive, I'm not describing marketing theory.

The sticker price is not a price. It's a down payment.

Here is my position: total cost of ownership—TCO—is the only honest way to compare medical equipment. The price on the quote is just the part of the iceberg that sits above the water. Underneath it sit installation costs, consumables, QC supplies, service contracts, training, downtime, compatibility, and the quiet clinical costs that only show up later.

• acquisition, freight, and installation
• consumables and quality-control materials
• operator training and retraining
• maintenance, parts, and downtime
• compatibility with existing inventory and infrastructure
• clinical consequences, complaints, and follow-up work

Some of those costs show up on a balance sheet. Others show up as a nurse's time, or a phone call from a patient wondering whether the glare they see at night is normal. That call is a cost too.

A lens is a better example than it looks like

Before I worked on the quality side, everything I'd read about intraocular lens selection focused on visual acuity. Refractive outcomes. Snellen lines. Those matter. But in practice, what drives post-op satisfaction is not only the line on the chart; it's the absence of visual disturbances—glare, halos, arcs, shadows. That's dysphotopsia.

Every time I review an intraocular lens, the first thing I ask for is the dysphotopsia data. The Envista Envy IOL dysphotopsia clinical studies are exactly the kind of document I want to see early. I'm not looking for an infographic. I want follow-up periods, patient-reported outcomes, and long term behavior. The Envista Envy IOL long term outcomes clinical data is the part that actually matters for cost. A patient who is unhappy with night vision may not need a surgical revision. But they might need extra appointments, phone calls, reassurance, or in some cases a lens exchange. Those costs land on the clinic, not on the purchase order.

That is why I have no patience for procurement teams that evaluate a lens by price alone. A lens with a higher number of dysphotopsia complaints can be more expensive in one year than a better-documented lens over five.

Let me be clear: I do not mean 'buy premium.' I mean buy with your eyes open.

Blood gas analyzer: the spreadsheet was wrong

I got this one wrong in 2024. We had two weeks to compare two blood gas analyzers, not the 30 days I would have wanted. The cheaper analyzer was about $8,000 less on the quote. I knew I should run a parallel evaluation with real clinical samples, but the deadline had already been set before the evaluation started. So we compared list prices, consumables, and service intervals on paper.

We missed the QC frequency. The lower-priced analyzer required quality-control testing before every shift—and in a busy lab, that meant roughly three extra QC ampules per day. The proprietary control material wasn't cheap. By my rough math, the QC expense erased most of the $8,000 saving within two years. And because the analyzer used a closed consumable system, the clinical team couldn't switch to a cheaper supplier to fix it.

Had I checked the IFU more carefully, the requirement was right there. I didn't, because we were in a hurry and the price looked good. The day the contract was signed, I had a knot in my stomach. It took eighteen months to confirm what it was telling me.

Training is another hidden line. A blood gas analyzer is only as fast as the people using it. If the interface isn't clear and daily maintenance is awkward, operators create workarounds, and workarounds are patient-safety issues. I've watched staff skip a QC check because it 'takes too long.' That's not just a user problem. That's a design and TCO problem.

Patient lifts make the same cost visible

A patient lift is a more obvious example. It's a mechanical device with a motor, battery, hanger bar, slings, and reprocessing requirements. It should not be bought like an office chair. Office chairs don't get body fluids on them and then need a validated disinfection procedure.

In a Q1 2024 audit, I found a sterilization lot trace for patient lift slings that didn't connect cleanly to the shipment dates. Under ISO 13485, traceability should allow you to follow a specific sling from raw material to patient. This lot didn't, and as a result, roughly 8,000 units sat quarantined for weeks. The vendor called the paperwork issue 'administrative.' It may have been. But if an incident happened, I would have had to stand in front of a regulator without a full lot trace. That cost is real.

Reprocessing validation is another line item that doesn't show up on a quote. Under AAMI ST79, sterilization methods need to be validated for the actual load. If a sling material can't tolerate routine reprocessing, the facility has to buy single-use alternatives or change protocols. That's a recurring cost that makes the list price almost meaningless.

There is also the compatibility trap. A patient lift bought at a bargain price might use a hanger bar that only fits the same brand's slings. If the unit is cheaper because the sling interface is proprietary, the cost follows you through every replacement. I watched a regional hospital save $400 per lift and then pay more than that across three years of replacement slings. I don't remember the exact invoice, but the direction was unmistakable.

What is a medical trolley?

The question 'what is a medical trolley?' sounds like an entry-level search, but I take it seriously. A medical trolley is a mobile clinical workstation: medication drawers, an IV pole, locking casters, chemical-resistant surfaces, and sometimes a work surface for emergency procedures. It is not a cheap office cart.

I'll give you the unglamorous version. A budget trolley can look fine for the first year. Then the caster brake starts slipping, the top drawer doesn't align, and the latch fails so the drawer opens when someone pushes the trolley. In a medication storage context, a drawer that opens by itself is an infection control and security issue. Replacing a 'value' trolley after 14 months costs about 80% of the original list price—and that doesn't count the time staff spent working around it.

So when someone asks what a medical trolley is, my answer is: it's a test of whether your purchasing team understands TCO.

But what if procurement says 'lowest bid'?

The usual objection is that procurement rules force you to accept the lowest bid. The actual phrase is usually 'lowest responsive bid.' Responsive means the bid meets the specification, not only the price. If the specification doesn't include QC frequency, sling compatibility, service uptime, and clinical follow-up costs, the specification is incomplete.

I've watched hospital systems include a five-year consumable cost column in the scoring matrix. It's practical, legal, and still too rare. And it doesn't require buying premium equipment. It requires knowing the total cost of the equipment you already need.

The budget timing objection is fair too. Capital budgets are crowded. But moving money from an operating budget to a capital budget is possible when finance can see five-year savings. What kills the conversation is a low initial price followed by surprise operating costs later.

The bottom line: price is what you pay, cost is what you live with

I'm not going to pretend I've perfected this. Last month I almost approved a sterilization claim because the summary looked familiar and I was moving too fast. We caught it before release, but that was luck, not process. Ever since I implemented a verification checklist in 2022, I've made fewer of those mistakes. Not zero. Fewer.

Every time I review a returned device, I look for the moment the cost became predictable. It was almost always earlier than the team expected. The 'cheaper' option failed because the training wasn't in the price. The 'value' trolley failed because the latch wasn't in the spec. The 'budget' lens generated calls because dysphotopsia was not in the evaluation criteria.

Here's what I'd put in an evaluation spec: consumable frequency, service response time, staff training hours, sling compatibility, reprocessing validation, and a column for post-market data. You don't need an MBA to score those. You need to be willing to stop the quote comparison at line one.

And yes, open the FDA 510(k) database before you compare anything. It tells you what was actually cleared. If the manufacturer's claims go beyond that, the rest of the conversation is not about price anymore.

If you only take one thing from this, take this: the question is not 'how much does it cost?' The question is 'what will it cost this organization over five years, including the 7pm phone call you didn't expect?' That is the number that should drive the decision.

The most expensive device isn't always the right answer. Neither is the cheapest. The right answer is the one where you can trace the total cost to a defensible number. Everything else is a guess.